Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF A Multicenter Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10314382" target="_blank" >RIV/00216208:11110/15:10314382 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/15:00059625

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jacc.2015.09.083" target="_blank" >http://dx.doi.org/10.1016/j.jacc.2015.09.083</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jacc.2015.09.083" target="_blank" >10.1016/j.jacc.2015.09.083</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF A Multicenter Study

Popis výsledku v původním jazyce

BACKGROUND The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure. The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse. OBJECTIVES The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS. METHODS The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal. Patients were adults with ejection fraction <= 25%, cardiac index <= 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant. RESULTS Fifty patients were enrolled at 10 centers. The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%). At 6 months, 88% of patients continued on support,

Název v anglickém jazyce

Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF A Multicenter Study

Popis výsledku anglicky

BACKGROUND The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure. The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse. OBJECTIVES The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS. METHODS The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal. Patients were adults with ejection fraction <= 25%, cardiac index <= 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant. RESULTS Fifty patients were enrolled at 10 centers. The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%). At 6 months, 88% of patients continued on support,

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the American College of Cardiology

ISSN

0735-1097

e-ISSN

—

Svazek periodika

66

Číslo periodika v rámci svazku

23

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

2579-2589

Kód UT WoS článku

000366095200001

EID výsledku v databázi Scopus

—